Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;26(3):725-731.
doi: 10.1007/s40477-023-00788-2. Epub 2023 May 5.

SIUMB recommendations on the use of ultrasound in neoplastic lesions of the gallbladder and extrahepatic biliary tract

Ilario de Sio  1 , Mirko D'Onofrio  2 , Paoletta Mirk  3 , Michele Bertolotto  4 , Kateryna Priadko  5 , Cosima Schiavone  6 , Vito Cantisani  7 , Giovanni Iannetti  8 , Gianfranco Vallone  9 , Gianpaolo Vidili  10 ; SIUMB experts committee
Collaborators, Affiliations

SIUMB recommendations on the use of ultrasound in neoplastic lesions of the gallbladder and extrahepatic biliary tract

Ilario de Sio et al. J Ultrasound. 2023 Sep.

Abstract

Extrahepatic biliary tract and gallbladder neoplastic lesions are relatively rare and hence are often underrepresented in the general clinical recommendations for the routine use of ultrasound (US). Dictated by the necessity of updated summarized review of current literature to guide clinicians, this paper represents an updated position of the Italian Society of Ultrasound in Medicine and Biology (SIUMB) on the use of US and contrast-enhanced ultrasound (CEUS) in extrahepatic biliary tract and gallbladder neoplastic lesions such as extrahepatic cholangiocarcinoma, gallbladder adenocarcinoma, gallbladder adenomyomatosis, dense bile with polypoid-like appearance and gallbladder polyps.

Keywords: Contrast-enhanced ultrasound; Extrahepatic biliary tract; Gallbladder; Neoplastic lesions; Ultrasound.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendation. BMJ. 2008;336:924–926. doi: 10.1136/bmj.39489.470347.AD. - DOI - PMC - PubMed
    1. Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):98–107. doi: 10.1111/liv.14086. - DOI - PubMed
    1. Madhusudhan KS, Gamanagatti S, Gupta AK. Imaging and interventions in hilar cholangiocarcinoma: a review. World J Radiol. 2015;7:28–44. doi: 10.4329/wjr.v7.i2.28. - DOI - PMC - PubMed
    1. Xu HX, Chen LD, Xie XY, Xie XH, Xu ZF, Liu GJ, Lin MX, Wang Z, Lu MD. Enhancement pattern of hilar cholangiocarcinoma: contrast-enhanced ultrasound versus contrast-enhanced computed tomography. Eur J Radiol. 2010;75:197–202. doi: 10.1016/j.ejrad.2009.04.060. - DOI - PubMed
    1. Bauditz J, Schade T, Wermke W. Sonographic diagnosis of hilar cholangiocarcinomas by the use of contrast agents. Ultraschall Med. 2007;28:161–167. doi: 10.1055/s-2007-962825. - DOI - PubMed